Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > ARCHIVE
ARCHIVE
- Mochida: Operating Profits Up 34% Driven by Good Sales of Epadel, Atelec
November 26, 2007
- Taiyo: Sales Up 7%, Operating Profits Down 1%
November 26, 2007
- Kissei: Urief, Glufast Surge, Bezatol, Cabaser Sink
November 26, 2007
- Towa: Profits Leap as a Result of Focus on Top-Priority Products
November 26, 2007
- Nippon Shinyaku Aims at Developing Many Medium-Sized Products: President Maekawa
November 26, 2007
- Nippon Chemiphar: Uralyt, Generics Drive Business
November 26, 2007
- Toyama Chemical: License Fees Revitalize Business
November 26, 2007
- Prescription Form to Be Changed again to Promote Use of Generics
November 26, 2007
- Yakult Honsha: Pharma Sales Up 31% Driven by Elplat
November 26, 2007
- R&D NEWS IN BRIEF
November 26, 2007
- Seikagaku Corp.: Artz Drives Sales 12.9%
November 26, 2007
- REGULATORY NEWS IN BRIEF
November 26, 2007
- Nissan Chemical:Pharma Sales Down to \3,415 Mil.
November 26, 2007
- MEDICAL DEVICE NEWS IN BRIEF
November 26, 2007
- Top-4 Wholesalers Keep Operating Profit Rates Above 1%
November 26, 2007
- There Is No Legal Ground for Ban on Kongo Shinryo: Court Ruling
November 26, 2007
- Mediceo Paltac to Expand Its Share on Market for Dispensing Pharmacies
November 26, 2007
- NEW PRODUCTS／POLA Pharma Launches Estradiol Gel
November 26, 2007
- Alfresa: Good Sales to Dispensing Pharmacies Drive Business
November 26, 2007
- MEDICAL FACILITIES & NURSING CARE NEWS IN BRIEF
November 26, 2007
ページ
Strategic Talent Acquisition in the Japanese Life Sciences Sector: Your Market Intelligence Briefing
Focus: How to Get the Talent You Need in a Tough MarketThe Japanese life sciences sector presents a challenging landscape for global companies. To succeed, you must move beyond reactive hiring and adopt a truly strategic talent acquisition model. Our…
Japan’s FY2026 drug price revision, officially announced on March 5, has landed poorly with the pharmaceutical industry — and the…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…